Relmada Therapeutics, Inc. (RLMD): Total Liabilities
$7.49M
As of 2025-12-31
$12.50M
As of 2026-06-30
-15.6%
3-year compound annual growth
-9.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.49M | -27.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $10.30M | -15.6% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $12.19M | -2.2% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $12.47M | -17.2% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $15.06M | +19.5% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $12.60M | +764.5% | 2022-03-25, Balance as of period end |
| 2019-12-31 | $1.46M | n/a | 2021-03-24, Balance as of period end |
| 2019-06-30 | $2.61M | -69.6% | 2021-03-24, Balance as of period end |
| 2018-06-30 | $8.56M | +521.9% | 2019-09-24, Balance as of period end |
| 2017-06-30 | $1.38M | -57.0% | 2018-09-28, Balance as of period end |
| 2016-06-30 | $3.20M | -79.5% | 2017-09-28, Balance as of period end |
| 2015-06-30 | $15.58M | -42.0% | 2016-09-09, Balance as of period end |
| 2014-06-30 | $26.87M | n/a | 2015-09-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | 2025-12-31 | $7.49M | -27.2% |
| Journey Medical Corp (DERM) | 2025-12-31 | $62.74M | +4.3% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $18.04M | -47.5% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $65.96M | +27.6% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $38.11M | +4.6% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $8.64M | -24.4% |
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $233.76M | +272.0% |
| Dogwood Therapeutics, Inc. (DWTX) | 2025-12-31 | $15.27M | -49.1% |
| vTv Therapeutics Inc. (VTVT) | 2025-12-31 | $25.46M | +6.2% |
Compare RLMD, DERM, ABUS, ETON side by side · Screen every company in Pharmaceutical Preparations ↗